Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Phase II Study Comparing the Safety, Tolerability and Beneficial Effects of Daily Doses of RC-1291 and Placebo in Patients With Cancer Anorexia/Cachexia

NCT00378131 is registered in ClinicalTrials.gov with Helsinn Therapeutics (U.S.), Inc as lead sponsor.

NCT NCT00378131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00378131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Phase II Study Comparing the Safety, Tolerability and Beneficial Effects of Daily Doses of RC-1291 and Placebo in Patients With Cancer Anorexia/Cachexia
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2006
Completion date
April 30, 2007
Enrollment
51 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

cancer cachexia